Quest Diagnostics Incorporated (NYSE:DGX) updated its FY17 earnings guidance on Thursday. The company provided earnings per share guidance of $5.37-5.52 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.45. The company issued revenue guidance of $7.64-7.72 billion, compared to the consensus revenue estimate of $7.66 billion.
A number of analysts have recently weighed in on the stock. Jefferies Group LLC upped their price target on shares of Quest Diagnostics to $96.00 in a report on Friday. Zacks Investment Research raised shares of Quest Diagnostics from a hold rating to a buy rating and set a $102.00 price target for the company in a report on Tuesday, January 24th. Canaccord Genuity set a $90.00 price target on shares of Quest Diagnostics and gave the stock a buy rating in a report on Thursday, October 20th. Mizuho reaffirmed a neutral rating and set a $88.00 price target on shares of Quest Diagnostics in a report on Wednesday, November 30th. Finally, Barclays PLC set a $85.00 price target on shares of Quest Diagnostics and gave the stock a hold rating in a report on Monday, November 14th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. Quest Diagnostics presently has a consensus rating of Hold and an average target price of $90.38.
Shares of Quest Diagnostics Incorporated (NYSE:DGX) opened at 92.72 on Monday. The firm has a market capitalization of $12.70 billion, a PE ratio of 20.56 and a beta of 0.66. The stock’s 50 day moving average is $92.18 and its 200 day moving average is $86.17. Quest Diagnostics Incorporated has a 52-week low of $59.66 and a 52-week high of $95.14.
Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Thursday, January 26th. The company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Quest Diagnostics had a net margin of 8.56% and a return on equity of 14.62%. The company earned $1.86 billion during the quarter, compared to analyst estimates of $1.86 billion. During the same period last year, the business earned $1.29 earnings per share. Quest Diagnostics’s revenue was up .6% compared to the same quarter last year. On average, equities research analysts forecast that Quest Diagnostics Incorporated will post $5.47 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, January 25th. Shareholders of record on Tuesday, January 10th were given a dividend of $0.45 per share. The ex-dividend date of this dividend was Friday, January 6th. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.40. This represents a $1.80 annualized dividend and a yield of 1.94%. Quest Diagnostics’s payout ratio is presently 40.00%.
A number of large investors have recently made changes to their positions in DGX. FIL Ltd raised its stake in shares of Quest Diagnostics by 33.2% in the second quarter. FIL Ltd now owns 352,328 shares of the company’s stock valued at $28,683,000 after buying an additional 87,899 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Quest Diagnostics during the second quarter valued at about $4,697,000. Janney Montgomery Scott LLC raised its stake in shares of Quest Diagnostics by 34.4% in the second quarter. Janney Montgomery Scott LLC now owns 10,963 shares of the company’s stock valued at $780,000 after buying an additional 2,808 shares during the last quarter. Public Sector Pension Investment Board raised its stake in shares of Quest Diagnostics by 16.0% in the second quarter. Public Sector Pension Investment Board now owns 26,783 shares of the company’s stock valued at $2,180,000 after buying an additional 3,700 shares during the last quarter. Finally, National Pension Service raised its stake in shares of Quest Diagnostics by 9.9% in the second quarter. National Pension Service now owns 113,401 shares of the company’s stock valued at $9,232,000 after buying an additional 10,230 shares during the last quarter. Institutional investors and hedge funds own 87.71% of the company’s stock.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others.